<p><strong>Primary Hypercholesterolemia:</strong>&nbsp;Ezetimibe co-administered with statin is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia who are not appropriately controlled with a statin alone.<br />
Ezetimibe monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia in whom a statin is considered inappropriate or is not tolerated.<br />
<br />
<strong>Prevention of Cardiovascular Events:</strong>&nbsp;Ezetimibe is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.<br />
<br />
<strong>Homozygous Familial Hypercholesterolaemia (HoFH):</strong>&nbsp;Ezetimibe co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).<br />
<br />
<strong>Homozygous Sitosterolemia (Phytosterolemia):</strong>&nbsp;Ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolemia</p>